EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Artificial Intelligence-Driven Antibody-Drug Conjugate Development for Chronic Neuropathic Pain: From Target Discovery to Clinical Translation

Yuan Liu, Qin Xie, Huixian Zhou, Krushi Shah, Siyuan Song

AI Med · 2026

DOI: 10.71423/aimed.20260606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AI Med, 2026. Verfasst von Yuan Liu und 4 weiteren Autor:innen. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic neuropathic pain affects 7–10% of the global population and imposes a substantial socioeconomic burden, yet existing pharmacological options remain inadequate in efficacy and burdened by systemic toxicity. Antibody-drug conjugates (ADCs) — engineered to deliver neuromodulatory payloads selectively to peripheral nociceptors — represent a compelling but unexplored therapeutic modality; no clinical-stage pain ADC currently exists. To the best of our knowledge based on a structured literature search (January 2000–March 2025) and targeted updates through 6 June 2026, this review provides a systematic and comprehensive conceptual framework mapping AI methodologies validated in oncology ADC development onto the unique challenges of chronic neuropathic pain. The framework spans five pipeline stages: multi-omics integration and graph neural networks for nociceptor-selective target prioritization (Nav1.7, TRPV1, P2X3, TrkA, CGRP receptor, ASIC3); structure prediction and protein language models for antibody engineering against transmembrane pain targets; generative AI for neuromodulatory payload design; deep learning for neural tissue pharmacokinetics and neurotoxicity prediction; and AI-driven patient stratification for precision clinical trial design. A unique three-layer optimization challenge — neural selectivity, analgesic potency, and systemic safety — distinguishes pain ADC AI from oncology ADC AI and defines the core design constraints of this review. Clinical precedent from FDA-approved anti-CGRP pathway antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and Phase III anti-NGF antibody trials establishes that peripheral nociceptor-targeting biologics are both feasible and clinically active, providing the biological foundation for the pain-ADC concept. Realizing this framework requires curated pain-ADC datasets, interpretable AI, and closed-loop platforms incorporating dorsal root ganglion (DRG) organoids.

Zitieren

APA

Liu, Y., Xie, Q., Zhou, H., Shah, K., & Song, S. (2026). Artificial Intelligence-Driven Antibody-Drug Conjugate Development for Chronic Neuropathic Pain: From Target Discovery to Clinical Translation. AI Med. https://doi.org/10.71423/aimed.20260606

Vancouver

Liu Y, Xie Q, Zhou H, Shah K, Song S. Artificial Intelligence-Driven Antibody-Drug Conjugate Development for Chronic Neuropathic Pain: From Target Discovery to Clinical Translation. AI Med. 2026. doi:10.71423/aimed.20260606

BibTeX
@article{Liu2026,
  author = {Liu, Yuan and Xie, Qin and Zhou, Huixian and Shah, Krushi and Song, Siyuan},
  title = {Artificial Intelligence-Driven Antibody-Drug Conjugate Development for Chronic Neuropathic Pain: From Target Discovery to Clinical Translation},
  journal = {AI Med},
  year = {2026},
  doi = {10.71423/aimed.20260606}
}
Kostenlos starten →